[go: up one dir, main page]

EA011859B9 - Соединения для адресной доставки препарата к ткани или органу-мишени - Google Patents

Соединения для адресной доставки препарата к ткани или органу-мишени

Info

Publication number
EA011859B9
EA011859B9 EA200601264A EA200601264A EA011859B9 EA 011859 B9 EA011859 B9 EA 011859B9 EA 200601264 A EA200601264 A EA 200601264A EA 200601264 A EA200601264 A EA 200601264A EA 011859 B9 EA011859 B9 EA 011859B9
Authority
EA
Eurasian Patent Office
Prior art keywords
targeted
compounds
tissue
monoclonal antibody
specificity
Prior art date
Application number
EA200601264A
Other languages
English (en)
Other versions
EA011859B1 (ru
EA200601264A1 (ru
Inventor
Стефан Гиллиес
Кин-Минг Ло
Ян Лэн
Рэкеш Верма
Original Assignee
Емд Лексиген Ресерч Сентер Корп.
Антисома Плк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Емд Лексиген Ресерч Сентер Корп., Антисома Плк filed Critical Емд Лексиген Ресерч Сентер Корп.
Publication of EA200601264A1 publication Critical patent/EA200601264A1/ru
Publication of EA011859B1 publication Critical patent/EA011859B1/ru
Publication of EA011859B9 publication Critical patent/EA011859B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящим изобретением предлагается соединение, содержащее участок адресной доставки и эффекторный участок, причем участок адресной доставки включает в себя или содержит моноклонное антитело, обладающее специфичностью в отношении карциноэмбрионального фибронектина или его фрагмента либо разновидности, которое несет на себе связывающую специфичность антигена моноклонного антитела-предшественника, а эффекторный участок включает в себя или содержит интерлейкин-12 или его функциональный фрагмент либо разновидность, отличающееся тем, что моноклонное антитело, обладающее специфичностью в отношении карциноэмбрионального фибронектина, присоединяется к участку карциноэмбрионального фибронектина, отличному от участка ED-B. Кроме того, изобретением предлагается кодирование этих соединений с помощью нуклеиновой кислоты и использование таких соединений в медицине, например, при лечении рака.
EA200601264A 2004-01-05 2005-01-05 Соединения для адресной доставки препарата к ткани или органу-мишени EA011859B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53430704P 2004-01-05 2004-01-05
PCT/GB2005/000007 WO2005066348A2 (en) 2004-01-05 2005-01-05 Interleukin-12 targeted to oncofoetal fibronectin

Publications (3)

Publication Number Publication Date
EA200601264A1 EA200601264A1 (ru) 2007-12-28
EA011859B1 EA011859B1 (ru) 2009-06-30
EA011859B9 true EA011859B9 (ru) 2013-07-30

Family

ID=34748996

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601264A EA011859B9 (ru) 2004-01-05 2005-01-05 Соединения для адресной доставки препарата к ткани или органу-мишени

Country Status (7)

Country Link
US (1) US8420087B2 (ru)
EP (1) EP1702069A2 (ru)
JP (1) JP2007517506A (ru)
AU (1) AU2005203962C1 (ru)
CA (1) CA2552590A1 (ru)
EA (1) EA011859B9 (ru)
WO (1) WO2005066348A2 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666809A1 (en) * 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Anti-cancer agent comprising anti-hb-egf antibody as active ingredient
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
PL3281952T3 (pl) 2007-10-30 2020-11-16 Philogen S.P.A. Antygen związany z reumatoidalnym zapaleniem stawów
BRPI1016204A2 (pt) * 2009-04-22 2016-04-19 Merck Patent Gmbh proteínas de fusão de anticorpos com sítios de ligação fcrn modificados
US9238080B2 (en) * 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
EP3437662B1 (en) * 2011-07-27 2021-02-17 Philogen S.p.A. Il-12 immunoconjugate
ES2743423T3 (es) 2012-10-03 2020-02-19 Philogen Spa Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN105543279A (zh) * 2014-10-30 2016-05-04 常州卡斯比生物科技有限公司 一种防治辐射线损伤、肿瘤治疗的IL-12/Fc融合蛋白的制备方法及其药剂
JP6735822B2 (ja) 2015-07-16 2020-08-05 フィロゲン・ソチエタ・ペル・アツィオーニ Ｉｌ２２免疫コンジュゲート
KR20180039726A (ko) * 2015-09-04 2018-04-18 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 인슐린 면역글로불린 융합 단백질
US10450349B2 (en) 2016-03-04 2019-10-22 Purdue Research Foundation Multivalent fibronectin-integrin binding compositions and methods of use thereof
WO2017214262A1 (en) 2016-06-07 2017-12-14 The Pacific Heart, Lung, & Blood Institute Compositions and methods for treating cancer
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
TWI844524B (zh) * 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物
AU2020291012A1 (en) 2019-06-12 2021-12-16 AskGene Pharma, Inc. Novel IL-15 prodrugs and methods of use thereof
US20220356221A1 (en) * 2019-09-28 2022-11-10 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029732A2 (en) * 1997-12-08 1999-06-17 Lexigen Pharmaceuticals Corporation Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
WO2002002143A2 (en) * 2000-06-29 2002-01-10 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
WO2003093478A1 (en) * 2002-04-30 2003-11-13 Molmed Spa Immunoconjugates for the treatment of tumours

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) * 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
NZ192465A (en) * 1978-12-22 1983-09-30 Biogen Nv Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) * 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4469797A (en) * 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) * 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8615701D0 (en) 1986-06-27 1986-08-06 Delta Biotechnology Ltd Stable gene integration vector
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
KR100195632B1 (ko) 1988-07-23 1999-06-15 스티븐 조지 가랜드 펩티드 및 dna 배열
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5242824A (en) 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
EP0406857B1 (en) * 1989-07-07 1995-05-24 Takeda Chemical Industries, Ltd. Proteins and production thereof
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
ATE369383T1 (de) 1989-12-22 2007-08-15 Hoffmann La Roche Monoklonale antikörper spezifisch für den zytotoxischen lymphozyten-reifefaktor
ATE158615T1 (de) 1990-03-20 1997-10-15 Univ Columbia Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
ATE311895T1 (de) * 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
AU689214B2 (en) 1994-02-01 1998-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Fusion proteins that include antibody and nonantibody portions
ES2162917T3 (es) 1994-05-13 2002-01-16 Biovation Ltd Mejoras en o relativas al suministro de peptidos.
EP0770135A1 (en) 1994-07-29 1997-05-02 Smithkline Beecham Plc Novel compounds
DK0706799T3 (da) 1994-09-16 2002-02-25 Merck Patent Gmbh Immunkonjugater II
JPH11501506A (ja) 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
CA2214629C (en) * 1995-03-10 2001-07-10 Genentech, Inc. Receptor activation by gas6
AU5893796A (en) 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
GB9511935D0 (en) 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
AU1407997A (en) 1995-12-01 1997-06-19 Beth Israel Hospital Il-12 p40 subunit fusion polypeptides and uses thereof
US6620413B1 (en) * 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
AU1520097A (en) 1995-12-27 1997-07-28 Genentech Inc. Ob protein derivatives having prolonged half-life
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5756541A (en) 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US6046310A (en) 1996-03-13 2000-04-04 Protein Design Labs., Inc. FAS ligand fusion proteins and their uses
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US5922685A (en) * 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
WO1998000127A1 (en) 1996-07-02 1998-01-08 Bar-Ilan University Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases
DK0826696T3 (da) * 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
ES2280083T3 (es) 1996-12-20 2007-09-01 Amgen Inc. Composiciones de proteinas de fusion ob y metodos.
US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
AU7132798A (en) 1997-04-17 1998-11-11 Amgen, Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
AU8182298A (en) 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
JP2002505086A (ja) 1998-02-25 2002-02-19 レキシジェン ファーマシューティカルズ コーポレイション 抗体ベースの融合タンパク質の循環半減期の増強
CZ20003767A3 (cs) 1998-04-15 2002-01-16 Lexigen Pharmaceuticals Corp. Kompozice pro indukci imunitní odpovědi vůči zvolenému typu buňek v organismu savce a její pouľití pro výrobu léčiva
RU2217168C2 (ru) 1998-04-17 2003-11-27 Лексиген Фармасьютикэлс Корпорейшн Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора простагландина
EP1105427A2 (en) * 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
CA2339331C (en) 1998-08-25 2011-03-01 Lexigen Pharmaceuticals Corporation Expression and export of angiogenesis inhibitors as immunofusins
US6335176B1 (en) * 1998-10-16 2002-01-01 Pharmacopeia, Inc. Incorporation of phosphorylation sites
JP2002534962A (ja) 1999-01-07 2002-10-22 レキシジェン ファーマシューティカルズ コーポレイション Ｆｃ融合タンパク質としての抗肥満症タンパク質の発現および輸送
ATE418340T1 (de) * 1999-05-06 2009-01-15 Univ Wake Forest Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen
CZ20014123A3 (cs) 1999-05-19 2002-06-12 Lexigen Pharmaceuticals Corp. Exprese a export interferonů-alfa jako Fc fúzních proteinů
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
ATE526039T1 (de) * 2000-02-24 2011-10-15 Philogen Spa Zusammensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen
KR20040074587A (ko) 2001-02-19 2004-08-25 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 인공 단백질
PL206701B1 (pl) 2001-03-07 2010-09-30 Merck Patent Gmbh Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
WO2002090566A2 (en) 2001-05-03 2002-11-14 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
JP2005507870A (ja) 2001-08-13 2005-03-24 ユニバーシティ・オブ・サザン・カリフォルニア 低毒性のインターロイキン−２突然変異体
CA2469151C (en) 2001-12-04 2013-08-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immunocytokines with modulated selectivity
JP2005534283A (ja) 2002-03-11 2005-11-17 フィロジェン ソチエタ ペル アツィオニ 抗体分子を用いての腫瘍脈管系の選択的標的化
CA2479212A1 (en) 2002-03-15 2003-09-25 Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029732A2 (en) * 1997-12-08 1999-06-17 Lexigen Pharmaceuticals Corporation Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
WO2002002143A2 (en) * 2000-06-29 2002-01-10 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
WO2003093478A1 (en) * 2002-04-30 2003-11-13 Molmed Spa Immunoconjugates for the treatment of tumours

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CARNEMOLLA B. ET AL.: "A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors" JOURNAL OF CELL BIOLOGY 1989 UNITED STATES, vol. 108, no. 3, 1989, pages 1139-1148, XP002342604, ISSN: 0021-9525, abstract, page 1140, right-hand column, paragraph RESULTS - page 1144, right-hand column, figure 5, table III *
DICKERSON ERIN B. ET AL.: "Development of an IL-12 fusion protein for molecular targeting of tumor vasculature" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, no. 41, March 2000 (2000-03), page 798, ABSTRACT NO. 5074, XP002342607 & 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH.; SAN FRANCISCO, CALIFORNIA, USA; APRIL 01-05, 2000, ISSN: 0197-016X, the whole document *
HALIN C. ET AL.: "Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature" NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 20, no. 3, March 2002 (2002-03), pages 264-269, XP002256784, ISSN: 1087-0156, the whole document *
HALIN CORNELIA ET AL.: "Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha." CANCER RESEARCH, vol. 63, no. 12, 15 June 2003 (2003-06-15), pages 3202-3210, XP002342601, ISSN: 0008-5472, abstract, figures, page 3204, right-hand column - page 3207, right-hand column *
HUANG X. ET AL.: "TUMOR INFARCTION IN MICE BY ANTIBODY-DIRECTED TARGETING OF TISSUE FACTOR TO TUMOR VASCULATURE" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 275, 24 January 1997 (1997-01-24), pages 547-550, XP002071588, ISSN: 0036-8075, the whole document *
LADELL KRISTIN ET AL.: "A combination of plasmid DNAs encoding murine fetal liver kinase 1 extracellular domain, murine interleukin-12, and murine interferon-gamma inducible protein-10 leads to tumor regression and survival in melanoma-bearing mice." JOURNAL OF MOLECULAR MEDICINE (BERLIN), vol. 81, no. 4, April 2003 (2003-04), pages 271-278, XP002342606, ISSN: 0946-2716, abstract, figures *
MAJEWSKI S. ET AL.: "INTERLEUKIN-12 INHIBITS ANGIOGENESIS INDUCED BY HUMAN TUMOR CELL LINES IN VIVO" JOURNAL OF INVESTIGATIVE DERMATOLOGY, NEW YORK, NY, US, vol. 106, no. 5, 1996, pages 1114-1118, XP000949299, ISSN: 0022-202X, abstract, page 1116-page 1117 *
PENG L.S. ET AL.: "Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3)" JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, vol. 21, no. 9, 2001, pages 709-720, XP002342605, ISSN: 1079-9907, abstract, page 712-page 715; figures, page 715, left-hand column, last paragraph - right-hand column, paragraph 2 *
THORPE P.E. ET AL.: "The First International Conference on Vascular Targeting: Meeting overview" CANCER RESEARCH 01 MAR 2003 UNITED STATES, vol. 63, no. 5, 1 March 2003 (2003-03-01), pages 1144-1147, XP002342602, ISSN: 0008-5472, page 1145, left-hand column *
VAN VLIET A.I. ET AL.: "Distribution of fibronectin isoforms in human renal disease" JOURNAL OF PATHOLOGY 2001 UNITED KINGDOM, vol. 193, no. 2, 2001, pages 256-262, XP002342603, ISSN: 0022-3417, abstract, page 257, left-hand column, last paragraph - right-hand column, paragraph 1, page 258; figure 1, page 260; table 2 *
VITI F. ET AL.: "Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis" CANCER RESEARCH 15 JAN 1999 UNITED STATES, vol. 59, no. 2, 15 January 1999 (1999-01-15), pages 347-352, XP002124782, ISSN: 0008-5472, abstract, page 348-page 350 *
ZHU Z. ET AL.: "INHIBITION OF TUMOR GROWTH AND METASTASIS BY TARGETING TUMOR-ASSOCIATED ANGIOGENESIS WITH ANTAGONISTS TO THE RECEPTORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR" INVESTIGATION NEW DRUGS, MARTINUS NIJHOFF PUBLISHERS, BOSTON, US, vol. 17, no. 3, 1999, pages 195-212, XP000940444, ISSN: 0167-6997, page 202, right-hand column *

Also Published As

Publication number Publication date
JP2007517506A (ja) 2007-07-05
AU2005203962B2 (en) 2010-10-07
US20070202103A1 (en) 2007-08-30
CA2552590A1 (en) 2005-07-21
EA011859B1 (ru) 2009-06-30
AU2005203962A1 (en) 2005-07-21
US8420087B2 (en) 2013-04-16
AU2005203962C1 (en) 2012-11-08
WO2005066348A2 (en) 2005-07-21
WO2005066348A3 (en) 2005-11-10
EP1702069A2 (en) 2006-09-20
EA200601264A1 (ru) 2007-12-28

Similar Documents

Publication Publication Date Title
EA011859B9 (ru) Соединения для адресной доставки препарата к ткани или органу-мишени
EA200600275A1 (ru) Цитотоксический конъюгат, специфичный по отношению к са6 антигену, и способы его применения
SG153825A1 (en) Multivalent immunoglobulin-based bioactive assemblies
UA95438C2 (ru) Биспецифические антитела, которые замещают функциональные белки
JP2009197002A5 (ru)
DE602004031714D1 (de) Anthracyclin-anti-cd74-antikörperkonjugate
JP2012525432A5 (ru)
WO1999066951A3 (en) Use of bi-specific antibodies for pre-targeting diagnosis and therapy
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
SI1629011T1 (sl) Humane molekule za vezavo anti hu cd
WO2005103081A3 (en) Human monoclonal antibodies against cd20
EP3300739A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
WO2008036449A3 (en) Chemical antibodies for immunotherapy and imaging
GEP20135826B (en) Novel antibodies used to treat cancer
WO2006110745A3 (en) Conjugated anti-psma antibodies
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
EA200800642A1 (ru) Специфичный к антигену са6 цитотоксический конъюгат и способы его применения
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2004069860A3 (en) Isg15-conjugated proteins
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
WO2008042941A3 (en) Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
WO2004100882A3 (en) Inhibition of drug binding to serum albumin
WO2002094194A3 (en) Compositions and methods for inhibiting metastasis

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ MD TJ TM RU

RH4A Grant of a duplicate of a eurasian patent
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ MD TJ TM RU